ALSO NOTED: Barrier Therapeutics plans $25M IPO; Innogenetics awarded $7M in Abbott dispute; and much more...

> Cytyc says its $374 million bid for Australia's Vision Systems offers investors more money and a quicker deal than Ventana Medical Systems' competing bid. Report

> Barrier Therapeutics plans to raise $25 million in a public offering. Report

> Belgium's Innogenetics announced that a jury had awarded it $7 million in a patent dispute with Abbott Laboratories. Report

> Chutes & Ladders: Omega Pharma has promoted Jan Cassiman to CEO, replacing Marc Coucke. Report

> Chutes & Ladders: BioBalance CEO Dennis O'Donnell has resigned. Release

And Finally... After virtually disappearing, whooping cough is back and physicians are mounting a new campaign calling for a fresh round of vaccinations. Article

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.